<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255840</url>
  </required_header>
  <id_info>
    <org_study_id>CIPRA-SA Project 1</org_study_id>
    <secondary_id>U19AI053217</secondary_id>
    <secondary_id>3U19AI053217-03S1</secondary_id>
    <secondary_id>3U19AI053217-04S1</secondary_id>
    <secondary_id>3U19AI053217-04</secondary_id>
    <nct_id>NCT00255840</nct_id>
  </id_info>
  <brief_title>Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities</brief_title>
  <official_title>&quot;Safeguard the Household&quot; - A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIPRA SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>CIPRA SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of several anti-HIV treatment
      strategies in resource-poor South African communities. The strategies being studied are using
      specially trained doctors or nurses to administer HIV care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The introduction of antiretroviral therapy (ART) for the treatment of HIV has dramatically
      improved morbidity and mortality for HIV infected people in the developed world. However,
      research data on the efficacy of ART regimens in developing countries, such as South Africa,
      are limited. There are an estimated 4.7 million HIV infected individuals in the South African
      population of about 40 million inhabitants. The greatest social impact may be achieved by
      treating an entire household affected by HIV to ensure maximum adherence to prescribed ART
      regimens and to minimize the sharing of antiretroviral drugs. This study will evaluate the
      effectiveness of ART given by an HIV-trained doctor compared to ART given by an HIV-trained
      primary health care nurse. Participants failing first-line therapy will receive a second-line
      regimen based on what medications are available at the clinic, with approval by the clinical
      safety team. Participants in this study will be recruited from resource-poor communities
      outside Johannesburg and Cape Town, South Africa.

      This study will last 5 years. HIV infected people and other HIV infected members of their
      household 16 years of age and older will be enrolled. Study participants will receive
      first-line ART consisting of efavirenz (EFV) once daily, lamivudine (3TC) twice daily, and
      stavudine (d4T) twice daily. Women of childbearing potential who are unwilling to use
      acceptable forms of contraception and who have CD4 counts less than 250 cells/mm3 will
      receive 3TC twice daily; nevirapine (NVP) daily for 2 weeks, then twice daily; and d4T twice
      daily. Women who are pregnant at baseline, who become pregnant on study treatment, or who are
      unwilling to use acceptable methods of contraception and have CD4 counts of 250 cells/mm3 or
      more, or children who were previously exposed to NVP will receive 3TC twice daily,
      lopinavir/ritonavir (LPV/r) twice daily, and d4T twice daily. Participants will be randomly
      assigned to one of two arms. Arm 1 will receive ART under the monitoring care of an
      HIV-trained medical doctor, while Arm 2 will receive ART under the monitoring care of an
      HIV-trained primary health care nurse with training in HIV diagnosis and treatment.
      Participants who fail their first-line regimen will receive a second-line regimen but will
      remain in their treatment arms.

      Study visits will occur at study entry; Weeks 2, 4, 8, and 12; and every 12 weeks thereafter.
      A physical exam, measurement of height and weight, tuberculosis (TB) and hepatitis B
      infection screening, blood collection, pill counts, and compliance/adherence and resource
      utilization counseling will occur at most visits. Participants will also be asked to complete
      quality of life and household cost questionnaires at selected visits. Study visits for
      participants who fail first-line treatment will occur at treatment failure, between Days 15
      and 30, Week 4 post-treatment failure, every 4 weeks until Week 48 post-treatment failure,
      and every 12 weeks thereafter. A targeted physical exam, measurement of height and weight, TB
      infection screening, blood collection, pill counts, and compliance/adherence and resource
      utilization counseling will occur at most visits. Participants will also be asked to complete
      quality of life and household cost questionnaires at selected visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Treatment Failure Rate of Participants on First Line Antiretroviral Therapy Monitored by Primary Health Care Nurses (Investigative Arm)is Not Inferior to the Cumulative Treatment Failure Rate of Participants Monitored by Doctors (Control Arm).</measure>
    <time_frame>96 weeks</time_frame>
    <description>Cumulative treatment failure is a composite endpoint made up of death, virological failure, toxicity failure and protocol-defined loss to follow-up failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Compare Subject Adherence to First Line Antiretroviral Treatment as Measured by Pill Count, Between the Two Primary Health Care Monitoring Models.</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Resistance HIV Mutations, Defined by Demonstration of Virologic Failure</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Overall Clinical Safety of Antiretroviral Therapy, as Measured by the Occurrence of Clinical and Laboratory Grade 3 and 4 Adverse Events, Between Primary Health Care Monitoring Arms.</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Estimate the Total and Incremental Costs, From the Provider and Societal Perspectives, of the Two Approaches (the Primary Health Care Sister and Doctor) to the Provision of Antiretrovirals in Primary Health Care Services in Each Study Site.</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">812</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study-specified Antiretroviral regimen under care of HIV-trained medical doctor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study-specified Antiretroviral regimen under care of HIV-trained primary care nurse</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Monitoring by an HIV-trained medical doctor</intervention_name>
    <description>Participants will receive care from an HIV-trained medical doctor</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Monitoring by an HIV-trained primary care nurse</intervention_name>
    <description>Participants will receive care from an HIV-trained primary care nurse</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>600 mg tablet taken orally daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>EFV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>150 mg tablet taken orally daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>400 mg lopinavir/100mg ritonavir tablet taken orally twice daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>LPV/RTV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>NVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
    <description>Tablet taken orally daily. Dosage depends on weight.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>d4T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  Current severe CDC Category B AIDS-defining illness (with the exception of a single
             episode of bacterial sepsis or a single episode of zoster), OR history of a severe CDC
             Category B or C AIDS-defining illness, OR one CD4 count less than 350 cells/mm3 within
             6 months prior to study entry

          -  Antiretroviral naive. A participant who previously received 6 weeks or less of
             post-exposure prophylaxis or short course therapy for the prevention of
             mother-to-child transmission are not excluded. More information on this criterion can
             be found in the protocol.

          -  Willing to use acceptable forms of contraception

          -  Parent or guardian willing to provide informed consent, if applicable

        Exclusion Criteria:

          -  Current newly diagnosed CDC Category C AIDS-defining opportunistic infection or
             condition requiring acute therapy at the time of study entry. More information on this
             criterion can be found in the protocol.

          -  Therapy with agents with significant systemic myelosuppressive, neurotoxic,
             pancreatotoxic, hepatotoxic, or cytotoxic potential within 30 days prior to study
             entry

          -  Require certain medications

          -  Current alcohol or substance abuse that, in the opinion of the investigator, may
             interfere with the study

          -  Uncontrolled diarrhea (more than 6 stools per day for 7 consecutive days) within 30
             days prior to study entry

          -  Diagnosis of or suspected acute hepatitis within 30 days prior to study entry

          -  Signs or symptoms of bilateral peripheral neuropathy of Grade 2 or greater at
             screening

          -  Inability to tolerate oral medication

          -  Any other clinical condition that, in the opinion of the investigator, may interfere
             with the study

          -  In the first trimester of pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McIntyre, MBChB, MRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Sanne, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the Witwatersrand, Thembaletu Clinic, Helen Joseph Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Wood, MBChB, FCP (SA)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, University of Cape Town</affiliation>
  </overall_official>
  <reference>
    <citation>Hosseinipour MC, Kazembe PN, Sanne IM, van der Horst CM. Challenges in delivering antiretroviral treatment in resource poor countries. AIDS. 2002;16 Suppl 4:S177-87. Review.</citation>
    <PMID>12699015</PMID>
  </reference>
  <reference>
    <citation>Sanne I, van der Horst C. Research as a path to wide-scale implementation of antiretroviral therapy in Africa. J HIV Ther. 2004 Sep;9(3):65-8. Review.</citation>
    <PMID>15534564</PMID>
  </reference>
  <reference>
    <citation>Wools-Kaloustian K, Kimaiyo S. Extending HIV care in resource-limited settings. Curr HIV/AIDS Rep. 2006 Nov;3(4):182-6. Review.</citation>
    <PMID>17032578</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <results_first_submitted>March 2, 2011</results_first_submitted>
  <results_first_submitted_qc>May 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2011</results_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>James McIntyre</name_title>
    <organization>CIPRA SA</organization>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV-positive adult participants were recruited from February 2005 to December 2007 from two primary health care clinics, one in Masiphumelele, Cape Town and the other in Soweto, Johannesburg.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Antiretroviral Therapy Monitored by Medical Officer</title>
          <description>First line antiretroviral regimen monitored by a HIV-trained medical doctor:
Stavudine (&gt;60 kg: 40 mg twice daily and &lt;60 kg: 30 mg twice daily)
Lamivudine (150mg twice daily) and
Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count &lt;250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count &gt; 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily).</description>
        </group>
        <group group_id="P2">
          <title>Antiretroviral Therapy Managed by Primary Health Care Nurse</title>
          <description>First line antiretroviral regimen monitored by HIV-trained primary health care nurse:
Stavudine (&gt;60 kg: 40 mg twice daily and &lt;60 kg: 30 mg twice daily)
Lamivudine (150mg twice daily) and
Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count &lt;250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count &gt; 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="408"/>
                <participants group_id="P2" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="334"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued intervention</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antiretroviral Therapy Monitored by Medical Officer</title>
          <description>First line antiretroviral regimen monitored by a HIV-trained medical doctor:
Stavudine (&gt;60 kg: 40 mg twice daily and &lt;60 kg: 30 mg twice daily)
Lamivudine (150mg twice daily) and
Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count &lt;250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count &gt; 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily).</description>
        </group>
        <group group_id="B2">
          <title>Antiretroviral Therapy Managed by Primary Health Care Nurse</title>
          <description>First line antiretroviral regimen monitored by HIV-trained primary health care nurse:
Stavudine (&gt;60 kg: 40 mg twice daily and &lt;60 kg: 30 mg twice daily)
Lamivudine (150mg twice daily) and
Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count &lt;250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count &gt; 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="408"/>
            <count group_id="B2" value="404"/>
            <count group_id="B3" value="812"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="408"/>
                    <measurement group_id="B2" value="404"/>
                    <measurement group_id="B3" value="812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2612388" spread="7.1934154"/>
                    <measurement group_id="B2" value="32.9739630" spread="7.3921786"/>
                    <measurement group_id="B3" value="33.12" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="408"/>
                    <measurement group_id="B2" value="404"/>
                    <measurement group_id="B3" value="812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>To Compare Subject Adherence to First Line Antiretroviral Treatment as Measured by Pill Count, Between the Two Primary Health Care Monitoring Models.</title>
        <time_frame>Throughout study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Resistance HIV Mutations, Defined by Demonstration of Virologic Failure</title>
        <time_frame>Throughout the study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Overall Clinical Safety of Antiretroviral Therapy, as Measured by the Occurrence of Clinical and Laboratory Grade 3 and 4 Adverse Events, Between Primary Health Care Monitoring Arms.</title>
        <time_frame>Throughout study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Estimate the Total and Incremental Costs, From the Provider and Societal Perspectives, of the Two Approaches (the Primary Health Care Sister and Doctor) to the Provision of Antiretrovirals in Primary Health Care Services in Each Study Site.</title>
        <time_frame>Throughout study</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Treatment Failure Rate of Participants on First Line Antiretroviral Therapy Monitored by Primary Health Care Nurses (Investigative Arm)is Not Inferior to the Cumulative Treatment Failure Rate of Participants Monitored by Doctors (Control Arm).</title>
        <description>Cumulative treatment failure is a composite endpoint made up of death, virological failure, toxicity failure and protocol-defined loss to follow-up failure.</description>
        <time_frame>96 weeks</time_frame>
        <population>The primary analysis was an intention-to-treat analysis of any treatment failure with use of Cox proportional hazards regression.</population>
        <group_list>
          <group group_id="O1">
            <title>Antiretroviral Therapy Monitored by Medical Officer</title>
            <description>First line antiretroviral regimen monitored by a HIV-trained medical doctor:
Stavudine (&gt;60 kg: 40 mg twice daily and &lt;60 kg: 30 mg twice daily)
Lamivudine (150mg twice daily) and
Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count &lt;250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count &gt; 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Antiretroviral Therapy Managed by Primary Health Care Nurse</title>
            <description>First line antiretroviral regimen monitored by HIV-trained primary health care nurse:
Stavudine (&gt;60 kg: 40 mg twice daily and &lt;60 kg: 30 mg twice daily)
Lamivudine (150mg twice daily) and
Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count &lt;250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count &gt; 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Treatment Failure Rate of Participants on First Line Antiretroviral Therapy Monitored by Primary Health Care Nurses (Investigative Arm)is Not Inferior to the Cumulative Treatment Failure Rate of Participants Monitored by Doctors (Control Arm).</title>
          <description>Cumulative treatment failure is a composite endpoint made up of death, virological failure, toxicity failure and protocol-defined loss to follow-up failure.</description>
          <population>The primary analysis was an intention-to-treat analysis of any treatment failure with use of Cox proportional hazards regression.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="404"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="39" upper_limit="49"/>
                    <measurement group_id="O2" value="48" lower_limit="43" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Antiretroviral Therapy Monitored by Medical Officer</title>
          <description>First line antiretroviral regimen monitored by a HIV-trained medical doctor:
Stavudine (&gt;60 kg: 40 mg twice daily and &lt;60 kg: 30 mg twice daily)
Lamivudine (150mg twice daily) and
Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count &lt;250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count &gt; 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily).</description>
        </group>
        <group group_id="E2">
          <title>Antiretroviral Therapy Managed by Primary Health Care Nurse</title>
          <description>First line antiretroviral regimen monitored by HIV-trained primary health care nurse:
Stavudine (&gt;60 kg: 40 mg twice daily and &lt;60 kg: 30 mg twice daily)
Lamivudine (150mg twice daily) and
Efavirenz (600mg daily). For women of child bearing potential with a CD4+ count &lt;250 cells/mm3, Nevirapine (200 mg daily x 14 days, then 200 mg twice daily) and for women with a CD4+ count &gt; 250 cells/mm3, Lopinavir/ritonavir (400/100mg twice daily).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hyphema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms NOS</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Right Upper Quadrant Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Ruptured Appendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Swelling of Legs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune Reconstitution Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abcess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Buboes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cerebral Toxoplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Chest Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Cryptococcal Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Diarrhoea Cryptosporidial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Disseminated Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hidradenitis Suppurativa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Joint Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Perineal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pneumocystis Carnii Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Tuberculosis Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Tuberculosis Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Wound Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chemical Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Motor Vehicle Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Smoke Inhalation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Soft Tissue Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Stab Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>ALT Increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="408"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>AST Increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>GGT Increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="408"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Loss of Weight</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lactate Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hyperlactataemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Insulin Dependent Diabetic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Lipodystrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Karposi's Sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Left Side Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Mental Retardation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Antepartum Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Abruptio Plancentae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Fetal Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hellp Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Incomplete Abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Normal Delivery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Parasuicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Vaginal Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bullous Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Drug Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Eczema Weeping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Seborrheic Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Stevens Johnson Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Assault</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Collapse Cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="408"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>GGT increased</sub_title>
                <description>Gamma Glutamyl Transferase</description>
                <counts group_id="E1" events="36" subjects_affected="29" subjects_at_risk="408"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlactatemia</sub_title>
                <counts group_id="E1" events="79" subjects_affected="71" subjects_at_risk="408"/>
                <counts group_id="E2" events="44" subjects_affected="43" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="408"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lipodystrophy</sub_title>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="408"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study design did not address nurse-initiated ART because the prescription of ART in South Africa is restricted to doctors. We noted a high rate of loss to follow-up, but this rate was similar to other resource-constrained settings.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Ian Sanne</name_or_title>
      <organization>CIPRA-SA</organization>
      <phone>+27 11 276 8800</phone>
      <email>isanne@witshealth.co.za</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

